- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EFPIA Efforts to Block Stolen Drugs in European Supply Chain
The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims.
The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims.
The European Stakeholder Model (ESM) reportedly offers a cost-effective technological solution using anti-tampering device together with 2D barcoding to verify the authenticity of medicinal products.
Because of loopholes in traceability systems across EU jurisdictions, stolen medicines are re-entering the legal trade in EU countries through fictitious or corrupt brokers. With EFPIA’s verification system, serial numbers corresponding to each packaging will be recorded in the system; in case of repackaging, a link between the originators’ serial numbers and the traders’ serial numbers at batch level will be secured in the system. This link, reports EFPIA, will prevent any re-introduction of stolen medicines on any EU markets.
Last week AIFA, the Italian Medicines Agency, reported that between 2006 and 2013 one in ten Italian hospitals registered thefts of pharmaceuticals.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
